Prasugrel

Udaya S. Tantry, Kevin P. Bliden, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyricline (a P2Y12 receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes. However, clopidogrel treatment is associated with a wide response variability and non-responsiveness in selected patients. The latter phenomenon is linked to the occurrence of recurrent ischaemic events including stent thrombosis in the recent studies. Prasugrel is a new thienopyricline derivative that produces more potent platelet inhibition and a rapid onset of action that is associated with irreversible P2Y12 receptor blockade. The latter properties of prasugrel may provide a superior alternative to clopidogrel, with less response variability and a decreased prevalence of non-responsiveness.

Original languageEnglish (US)
Pages (from-to)1627-1633
Number of pages7
JournalExpert Opinion on Investigational Drugs
Volume15
Issue number12
DOIs
Publication statusPublished - Dec 2006

    Fingerprint

Keywords

  • Non-responsiveness
  • Platelet inhibition
  • Prasugrel
  • Thienopyridine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Tantry, U. S., Bliden, K. P., & Gurbel, P. A. (2006). Prasugrel. Expert Opinion on Investigational Drugs, 15(12), 1627-1633. https://doi.org/10.1517/13543784.15.12.1627